Cargando…

9G4 Autoreactivity Is Increased in HIV-Infected Patients and Correlates with HIV Broadly Neutralizing Serum Activity

The induction of a broadly neutralizing antibody (BNAb) response against HIV-1 would be a desirable feature of a protective vaccine. Vaccine strategies thus far have failed to elicit broadly neutralizing antibody responses; however a minority of HIV-infected patients do develop circulating BNAbs, fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobie, James J., Alcena, Danielle C., Zheng, Bo, Bryk, Peter, Mattiacio, Jonelle L., Brewer, Matthew, LaBranche, Celia, Young, Faith M., Dewhurst, Stephen, Montefiori, David C., Rosenberg, Alexander F., Feng, Changyong, Jin, Xia, Keefer, Michael C., Sanz, Ignacio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329433/ https://www.ncbi.nlm.nih.gov/pubmed/22530008 http://dx.doi.org/10.1371/journal.pone.0035356

Ejemplares similares

9G4+ Antibodies Isolated from HIV-Infected Patients Neutralize HIV-1 and Have Distinct Autoreactivity Profiles
por: Alcéna, Danielle C., et al.
Publicado: (2013)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
por: Pincus, Seth H., et al.
Publicado: (2021)

Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques
por: Rosenberg, Yvonne J., et al.
Publicado: (2016)

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity
por: Rubio, Adonis A., et al.
Publicado: (2021)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2018)

Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
por: Bajic, Goran, et al.
Publicado: (2019)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants
por: Martinez, David R., et al.
Publicado: (2020)

CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques
por: Sarkar, Sanghita, et al.
Publicado: (2021)

Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021)

HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site
por: McCurley, Nathanael P., et al.
Publicado: (2017)

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments
por: Hraber, Peter, et al.
Publicado: (2017)

Autoreactivity and broad neutralization of antibodies against HIV-1 are governed by distinct mutations: Implications for vaccine design strategies
por: Li, Xiaojun, et al.
Publicado: (2022)

The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat
por: Montefiori, David C., et al.
Publicado: (2021)

Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop
por: Qin, Yali, et al.
Publicado: (2015)

Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies
por: Sahoo, Anusmita, et al.
Publicado: (2022)

Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers
por: Nyanhete, Tinashe E., et al.
Publicado: (2021)

CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses
por: Lewis, Phoebe E., et al.
Publicado: (2020)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques
por: Jones, Andrew T., et al.
Publicado: (2018)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Optimization and validation of the HIV-1 neutralizing antibody assay in A3R5 cells
por: Sarzotti-Kelsoe, M, et al.
Publicado: (2012)

Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques
por: Rosenberg, Yvonne J., et al.
Publicado: (2019)

Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine
por: Cai, Hui, et al.
Publicado: (2018)

Immunization of Rabbits with Highly Purified, Soluble, Trimeric Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Induces a Vigorous B Cell Response and Broadly Cross-Reactive Neutralization
por: Quinnan, Gerald V., et al.
Publicado: (2014)

Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
por: Khattar, Sunil K., et al.
Publicado: (2015)

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies
por: Webb, Nicholas E., et al.
Publicado: (2015)

The broad spectrum of pathogenic autoreactivity
por: Santambrogio, Laura, et al.
Publicado: (2022)

Detection of HIV-1 Neutralizing Antibodies in a Human CD4(+)/CXCR4(+)/CCR5(+) T-Lymphoblastoid Cell Assay System
por: McLinden, Robert J., et al.
Publicado: (2013)

Autoreactivity of Broadly Neutralizing Influenza Human Antibodies to Human Tissues and Human Proteins
por: Khurana, Surender, et al.
Publicado: (2020)

Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma
por: Kumar, Amit, et al.
Publicado: (2018)

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
por: Capucci, Silvia, et al.
Publicado: (2017)

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
por: Pinto, Dora, et al.
Publicado: (2019)

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1
por: Wee, Edmund G., et al.
Publicado: (2019)

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1
por: Wee, Edmund G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rkpgjik0l29h35c3f7vste4aq9